News
DGX
153.10
+1.04%
1.58
Weekly Report: what happened at DGX last week (1216-1220)?
Weekly Report · 5h ago
DGX Dividend Yield Pushes Past 2%
NASDAQ · 3d ago
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Benzinga · 3d ago
Quest Diagnostics deal sends Mainz higher
Seeking Alpha · 3d ago
August 2025 Options Now Available For Quest Diagnostics (DGX)
NASDAQ · 3d ago
Mainz Biomed forms agreement with Quest Diagnostics
TipRanks · 4d ago
Mainz Biomed Forms Agreement With Quest Diagnostics To Support Commercialization Of Mainz Biomed's NextGen Screening Test For Colorectal Cancer
Benzinga · 4d ago
DGX Factor-Based Stock Analysis
NASDAQ · 4d ago
Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Simply Wall St · 5d ago
Morgan Stanley ups Quest to overweight from equal weight
Seeking Alpha · 5d ago
Pfizer provides FY25 outlook, McCormick in talks for Sauer Brands: Morning Buzz
TipRanks · 5d ago
Stocks Decline Ahead of Wednesday’s FOMC Meeting Results
Barchart · 5d ago
Tesla upgraded, MongoDB initiated: Wall Street’s top analyst calls
TipRanks · 5d ago
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 6d ago
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Benzinga · 6d ago
Quest Diagnostics Raised to Overweight From Equal-Weight by Morgan Stanley
Dow Jones · 6d ago
Quest Diagnostics Price Target Raised to $172.00/Share From $145.00 by Morgan Stanley
Dow Jones · 6d ago
Morgan Stanley Upgrades Quest Diagnostics to Overweight, Raises Price Target to $172
Benzinga · 6d ago
Quest Diagnostics upgraded to Overweight from Equal Weight at Morgan Stanley
TipRanks · 6d ago
More
Webull provides a variety of real-time DGX stock news. You can receive the latest news about Quest Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company also focuses on artificial intelligence (AI) and digital pathology solutions for biopharmaceutical companies and pathology laboratories. It has implemented AI, digital and automation technologies across several laboratory and business functions.